Anti-Hu CD180 Purified

CD180, also known as RP105 (or Bgp95, LY64) is a type I membrane glycoprotein of Toll-like receptor (TLR) family. Its cytoplasmic tail is short and unlike the TLRs, it lacks the TIR domain. CD180 expression is dependent on the coexpression of its helper molecule, MD-1, and mirrors that of TLR4 on antigen-presenting cells. CD180 regulates recognition of LPS and signaling in B cells, via interacting directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligands. Ligation of CD180 by monoclonal antibodies leads to B cell activation, upregulation of CD80/CD86, and increase in cell size.

Product Specifications

Certification

RUO

Reactivity

Human

Immunogen

Human tonsillar B cells

Target Antigen

CD180

Clone

G28-8

Applications

FC (QC tested), IP

Concentration

1 mg/mL

Format

Purified

Buffer

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

References & Citations

*Valentine MA, Clark EA, Shu GL, Norris NA, Ledbetter JA: Antibody to a novel 95-kDa surface glycoprotein on human B cells induces calcium mobilization and B cell activation. J Immunol. 1988 Jun 15;140 (12) :4071-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/3259604, *Clark EA, Shu GL, Lüscher B, Draves KE, Banchereau J, Ledbetter JA, Valentine MA: Activation of human B cells. Comparison of the signal transduced by IL-4 to four different competence signals. J Immunol. 1989 Dec 15;143 (12) :3873-80., URL: https://www.ncbi.nlm.nih.gov/pubmed/2480376, *Olson NE, Graves JD, Shu GL, Ryan EJ, Clark EA: Caspase activity is required for stimulated B lymphocytes to enter the cell cycle. J Immunol. 2003 Jun 15;170 (12) :6065-72., URL: http://www.ncbi.nlm.nih.gov/pubmed

Other References

*Kikuchi Y, Koarada S, Tada Y, Ushiyama O, Morito F, Suzuki N, Ohta A, Horiuchi T, Miyake K, Nagasawa K: Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells. Ann Rheum Dis. 2001 Dec;60 (12) :1137-40., URL: https://www.ncbi.nlm.nih.gov/pubmed/11709456, *Divanovic S, Trompette A, Petiniot LK, Allen JL, Flick LM, Belkaid Y, Madan R, Haky JJ, Karp CL: Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. J Leukoc Biol. 2007 Aug;82 (2) :265-71., URL: https://www.ncbi.nlm.nih.gov/pubmed/17470533, *Yazawa N, Fujimoto M, Sato S, Miyake K, Asano N, Nagai Y, Takeuchi O, Takeda K, Okochi H, Akira S, Tedder TF, Tamaki K: CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood. 2003 Aug 15;102 (4) :1374-80., URL: https://www.ncbi.nlm.nih.gov/pubmed/12714520, *Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL: Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol. 2005 Jun;6 (6) :571-8. , URL: https://www.ncbi.nlm.nih.gov/pubmed/15852007

Storage Conditions

Store at 2-8°C. Do not freeze.

Specificity

The mouse monoclonal antibody G28-8 recognizes an extracellular epitope of CD180, a 95-105 kDa TLR-like glycoprotein expressed on peripheral blood monocytes and dendritic cells, mantle zone B cells and marginal zone B cells, but very weakly on germinal center B cells.